Gallagher KE


16 results

Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21.Lucinde RK, Mugo D, Bottomley C, Karani A, Gardiner E, Aziza R, Gitonga JN, Karanja H, Nyagwange J, Tuju J, Wanjiku P, Nzomo E, Kamuri E, Thuranira K, Agunda S, Nyutu G, Etyang AO, Adetifa IMO, Kagucia E, Uyoga S, Otiende M, Otieno E, Ndwiga L, Agoti CN, Aman RA, Mwangangi M, Amoth P, Kasera K, Nyaguara A, Ng'ang'a W, Ochola LB, Namdala E, Gaunya O, Okuku R, Barasa E, Bejon P, Tsofa B, Ochola-Oyier LI, Warimwe GM, Agweyu A, Scott JAG, Gallagher KE
PLoS One, (2022). 17:e0265478

COVID-19 Vaccine Acceptability Among Healthcare Facility Workers in Sierra Leone, the Democratic Republic of Congo and Uganda: A Multi-Centre Cross-Sectional Survey.Whitworth HS, Kitonsa J, Kasonia K, Tindanbil D, Kafeero P, Bangura J, Nije Y, Tetsa Teta D, Greenwood B, Kavunga-Membo H, Leigh B, Ruzagira E, Gallagher KE, Watson-Jones D
Int J Public Health, (2022). 67:1605113

Social mixing patterns relevant to infectious diseases spread by close contact in urban Blantyre, Malawi.Thindwa D, Jambo KC, Ojal J, MacPherson P, Dennis Phiri M, Pinsent A, Khundi M, Chiume L, Gallagher KE, Heyderman RS, Corbett EL, French N, Flasche S
Epidemics, (2022). 40:100590

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Kohn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D, EBLstudy group
Lancet Infect Dis, (2022). 22:97-109

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Kohn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D, EBLstudy group
Lancet Infect Dis, (2022). 22:110-122

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.Kagucia EW, Gitonga JN, Kalu C, Ochomo E, Ochieng B, Kuya N, Karani A, Nyagwange J, Karia B, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Ajuck H, Mukabi D, Moracha W, Bulimu D, Andanje N, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG, Magarini Sub-County TDA SARS-CoV-2 Serosurveillance Team, The Busia County TDA SARS-CoV-Serosurveillance Team
Open Forum Infect Dis, (2021). 8:ofab314

Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review.Lucinde RK, Ong'ayo G, Houlihan C, Bottomley C, Goldblatt D, Scott JAG, Gallagher KE
Vaccine, (2021). 39:5095-5105

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, Karanja HK, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Bottomley C, Kagucia EW, Gallagher KE, Etyang A, Voller S, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Nat Commun, (2021). 12:3966

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Science, (2021). 371:79-82

Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021..Uyoga S, Otiende M, Adetifa IMO, Karanja HK, Gitonga J, Mugo D, Makale J, Tawa B, Singilai A, Nyagwange J, Tuju J, Aman R, Mwangangi M, Amoth P, Kasera K, Ng’ang’a W, Kilonzo N, Chege E, Yegon C, Rotich T, Orgut I, Kagucia EW, Gallagher KE, Etyang A, Voller S, Bottomley C, Lambe T, Wright D, Tsofa B, Mwangangi J, Barasa E, Bejon P, Ochola-Oyier LI, Warimwe GM, Scott JAG, Agweyu A
1st International Conference on Public Health in Africa (CPHIA), (2021). :

High anti-SARS-CoV-2 IgG antibody seroprevalence among long-distance trucking crews in Kenya within one year of the COVID-19 pandemic..Kagucia EW, Gitonga JN, Kalu C, Kuya N, Ochieng B, Karia B, Ochomo E, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The TDA SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng’ang’a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Characteristics of SARS-CoV-2 infections in households in rural coastal Kenya: a prospective genomic study..Agoti CN, Nyiro J, Murunga N, Lambisia AW, Mohammed KS, de Laurent ZR, Morobe JM, Mburu MW, Ndwiga L, Ongera EM, Makori T, Musyoki J, Mwangangi J, Tsofa B, Ochola-Oyier LI, Bejon P, Githinji G, Nokes DJ, Gallagher KE
1st International Conference on Public Health in Africa (CPHIA-2021), (2021). :

Serosurveillance for SARS-CoV-2 Antibodies in a cohort of Health Care Workers in Kenya..Etyang AO, Lucinde R, Gitonga JN, Kalu C, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The HCW SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng’ang’a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Vaccine strategies to reduce the burden of pneumococcal disease in HIV-infected adults in Africa.Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S
Expert Rev Vaccines, (2020). 19:1085-1092

Surveillance of endemic human coronaviruses (HCoV-NL63, OC43 and 229E) associated with childhood pneumonia in Kilifi, Kenya.Otieno GP, Murunga N, Agoti CN, Gallagher KE, Awori JO, Nokes DJ
Wellcome Open Res, (2020). 5:150

The Predictive Performance of a Pneumonia Severity Score in Human Immunodeficiency Virus-negative Children Presenting to Hospital in 7 Low- and Middle-income Countries.Gallagher KE, Knoll MD, Prosperi C, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Howie SRC, Kotloff KL, Levine OS, Madhi SA, Murdoch DR, O'Brien KL, Thea DM, Awori JO, Baillie VL, Ebruke BE, Goswami D, Kamau A, Maloney SA, Moore DP, Mwananyanda L, Olutunde EO, Seidenberg P, Sissoko S, Sylla M, Thamthitiwat S, Zaman K, Scott JAG
Clin Infect Dis, (2020). 70:1050-1057